US FDA Approves 1st-Ever Drug To Combat Sleep Apnea

Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop selling off-brand versions of the weight-loss drugs. The FDA has issued warnings against the off-brand versions, citing safety concerns.
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking it the first medication for certain patients with the condition.
The popular weight-loss drug Zepbound can now be used to treat sleep apnea
The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.
Lilly Rises on FDA Approval of Weight-Loss Drug Zepbound for Sleep Apnea
Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with sleep apnea and obesity, the drugmaker said after the bell Friday.Trials of the Lilly drug found that it helped reduce the number of breathing disruptions in an average night of sleep.
FDA approves first medication for obstructive sleep apnea, which also promotes weight loss
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.
Eli Lilly to test weight loss drug Zepbound to treat addiction
Weight loss injections have become a popular choice to help people curb their appetite, but can they curb addiction, as well?
FDA Approves Zepbound for Obstructive Sleep Apnea
FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
Bloomberg L.P. on MSN8d
Lilly’s US Weight-Loss Drug Shortage Ends, Curtailing Copies
Eli Lilly & Co.’s diabetes and weight-loss drugs Mounjaro and Zepbound are no longer in short supply in the US, which ...
Eli Lilly to end 2024 among best in Big Pharma; Novo among worst
Eli Lilly (LLY) emerges among the top performers in Big Pharma in 2024 with obesity drug success, while Novo Nordisk (NVO) ...
The Motley Fool on MSN1d
Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.
Novo's Ozempic is approved by the U.S. Food and Drug Administration ... momentum against Novo in weight loss while ...